Endocrinology news and related features from the GM archive, for GPs and other medical professionals treating the ageing patient.
New diabetes drug is accepted for use within NHS Scotland
Ensure people with type 2 diabetes are involved in decisions about their care
International study prompts rethink on the rise of diabetes in cities
'Diabetes smartphone' launched ahead of World Diabetes Day
Low diagnosis of TDS shown up by new data
Twenty new Clinical Champions for Diabetes UK
People living with diabetes not managing night-time hypos survey shows
New drug reduces risk of cardiovascular death in type 2 diabetes patients
Results from study looking at a new type 2 diabetes drug, empagliflozin(Jardiance), have demonstrated it significantly reduced the risk of the combined endpoint of cardiovascular (CV) death, non-fatal heart attack or non-fatal stroke by 14% (compared to placebo ) in patients with type 2 diabetes at high risk of CV events. All patients in the study received a background standard of care for cardiovascular disease. There was a significant 38% risk reduction in CV death, with no significant difference in the risk reduction of non-fatal heart attack or non-fatal stroke.